Low levels of IgM and IgA recognizing acetylated C1-inhibitor peptides are associated with systemic lupus erythematosus in Taiwanese women

研究成果: 雜誌貢獻文章

1 引文 (Scopus)

摘要

The objective of this study was to identify novel acetylation (Ac) modifications of the C1-inhibitor (C1-INH) and explain the association of the levels of autoantibodies against acetylated C1-INH peptides with the risk of developing systemic lupus erythematosus (SLE). Ac modifications of the C1-INH were identified and validated through in-gel digestion, nano-liquid chromatography-tandem mass spectrometry, immunoprecipitation, and Western blotting by using serum protein samples obtained from patients with SLE and age-matched healthy controls (HCs). In addition, the levels of serum C1-INH, Ac-protein adducts, and autoantibodies against unmodified and acetylated C1-INH peptides were measured. C1-INH levels in patients with SLE were significantly lower than those in HCs by 1.53-fold (p = 0.0008); however, Ac-protein adduct concentrations in patients with SLE were significantly higher than those in HCs by 1.35-fold (p = 0.0009). Moreover, immunoglobulin M (IgM) anti-C1-INH367-385 Ac and IgA anti-C1-INH367-385 Ac levels in patients with SLE were significantly lower than those in HCs. The low levels of IgM anti-C1-INH367-385 (odds ratio [OR] = 4.725, p < 0.001), IgM anti-C1-INH367-385 Ac (OR = 4.089, p = 0.001), and IgA anti-C1-INH367-385 Ac (OR = 5.566, p < 0.001) indicated increased risks for the development of SLE compared with HCs.

原文英語
文章編號1645
期刊Molecules
24
發行號9
DOIs
出版狀態已發佈 - 一月 1 2019

指紋

C1 peptide
acetylation
Acetylation
Systemic Lupus Erythematosus
inhibitors
Immunoglobulin A
peptides
Immunoglobulin M
Peptides
Odds Ratio
proteins
serums
Autoantibodies
adducts
Complement C1 Inhibitor Protein
Liquid chromatography
liquid chromatography
Tandem Mass Spectrometry
Immunoprecipitation

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

引用此文

@article{0a04cccd6ad249c18c7675592c84e3a1,
title = "Low levels of IgM and IgA recognizing acetylated C1-inhibitor peptides are associated with systemic lupus erythematosus in Taiwanese women",
abstract = "The objective of this study was to identify novel acetylation (Ac) modifications of the C1-inhibitor (C1-INH) and explain the association of the levels of autoantibodies against acetylated C1-INH peptides with the risk of developing systemic lupus erythematosus (SLE). Ac modifications of the C1-INH were identified and validated through in-gel digestion, nano-liquid chromatography-tandem mass spectrometry, immunoprecipitation, and Western blotting by using serum protein samples obtained from patients with SLE and age-matched healthy controls (HCs). In addition, the levels of serum C1-INH, Ac-protein adducts, and autoantibodies against unmodified and acetylated C1-INH peptides were measured. C1-INH levels in patients with SLE were significantly lower than those in HCs by 1.53-fold (p = 0.0008); however, Ac-protein adduct concentrations in patients with SLE were significantly higher than those in HCs by 1.35-fold (p = 0.0009). Moreover, immunoglobulin M (IgM) anti-C1-INH367-385 Ac and IgA anti-C1-INH367-385 Ac levels in patients with SLE were significantly lower than those in HCs. The low levels of IgM anti-C1-INH367-385 (odds ratio [OR] = 4.725, p < 0.001), IgM anti-C1-INH367-385 Ac (OR = 4.089, p = 0.001), and IgA anti-C1-INH367-385 Ac (OR = 5.566, p < 0.001) indicated increased risks for the development of SLE compared with HCs.",
keywords = "Acetylation, Autoantibody isotype, C1-inhibitor, Serum, Systemic lupus erythematosus",
author = "Tsai, {Kai Leun} and Liao, {Chen Chung} and Chang, {Yu Sheng} and Huang, {Ching Wen} and Huang, {Yu Chu} and Chen, {Jin Hua} and Lin, {Sheng Hong} and Tai, {Chih Chun} and Lin, {Yi Fang} and Lin, {Ching Yu}",
year = "2019",
month = "1",
day = "1",
doi = "10.3390/molecules24091645",
language = "English",
volume = "24",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

TY - JOUR

T1 - Low levels of IgM and IgA recognizing acetylated C1-inhibitor peptides are associated with systemic lupus erythematosus in Taiwanese women

AU - Tsai, Kai Leun

AU - Liao, Chen Chung

AU - Chang, Yu Sheng

AU - Huang, Ching Wen

AU - Huang, Yu Chu

AU - Chen, Jin Hua

AU - Lin, Sheng Hong

AU - Tai, Chih Chun

AU - Lin, Yi Fang

AU - Lin, Ching Yu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The objective of this study was to identify novel acetylation (Ac) modifications of the C1-inhibitor (C1-INH) and explain the association of the levels of autoantibodies against acetylated C1-INH peptides with the risk of developing systemic lupus erythematosus (SLE). Ac modifications of the C1-INH were identified and validated through in-gel digestion, nano-liquid chromatography-tandem mass spectrometry, immunoprecipitation, and Western blotting by using serum protein samples obtained from patients with SLE and age-matched healthy controls (HCs). In addition, the levels of serum C1-INH, Ac-protein adducts, and autoantibodies against unmodified and acetylated C1-INH peptides were measured. C1-INH levels in patients with SLE were significantly lower than those in HCs by 1.53-fold (p = 0.0008); however, Ac-protein adduct concentrations in patients with SLE were significantly higher than those in HCs by 1.35-fold (p = 0.0009). Moreover, immunoglobulin M (IgM) anti-C1-INH367-385 Ac and IgA anti-C1-INH367-385 Ac levels in patients with SLE were significantly lower than those in HCs. The low levels of IgM anti-C1-INH367-385 (odds ratio [OR] = 4.725, p < 0.001), IgM anti-C1-INH367-385 Ac (OR = 4.089, p = 0.001), and IgA anti-C1-INH367-385 Ac (OR = 5.566, p < 0.001) indicated increased risks for the development of SLE compared with HCs.

AB - The objective of this study was to identify novel acetylation (Ac) modifications of the C1-inhibitor (C1-INH) and explain the association of the levels of autoantibodies against acetylated C1-INH peptides with the risk of developing systemic lupus erythematosus (SLE). Ac modifications of the C1-INH were identified and validated through in-gel digestion, nano-liquid chromatography-tandem mass spectrometry, immunoprecipitation, and Western blotting by using serum protein samples obtained from patients with SLE and age-matched healthy controls (HCs). In addition, the levels of serum C1-INH, Ac-protein adducts, and autoantibodies against unmodified and acetylated C1-INH peptides were measured. C1-INH levels in patients with SLE were significantly lower than those in HCs by 1.53-fold (p = 0.0008); however, Ac-protein adduct concentrations in patients with SLE were significantly higher than those in HCs by 1.35-fold (p = 0.0009). Moreover, immunoglobulin M (IgM) anti-C1-INH367-385 Ac and IgA anti-C1-INH367-385 Ac levels in patients with SLE were significantly lower than those in HCs. The low levels of IgM anti-C1-INH367-385 (odds ratio [OR] = 4.725, p < 0.001), IgM anti-C1-INH367-385 Ac (OR = 4.089, p = 0.001), and IgA anti-C1-INH367-385 Ac (OR = 5.566, p < 0.001) indicated increased risks for the development of SLE compared with HCs.

KW - Acetylation

KW - Autoantibody isotype

KW - C1-inhibitor

KW - Serum

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85065300865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065300865&partnerID=8YFLogxK

U2 - 10.3390/molecules24091645

DO - 10.3390/molecules24091645

M3 - Article

C2 - 31027344

AN - SCOPUS:85065300865

VL - 24

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 9

M1 - 1645

ER -